Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2021; 13(4): 216-222
Published online Apr 15, 2021. doi: 10.4251/wjgo.v13.i4.216
Latest therapeutic target for gastric cancer: Anthrax toxin receptor 1
Ke-Ran Sun, Hui-Fang Lv, Bei-Bei Chen, Cai-Yun Nie, Jing Zhao, Xiao-Bing Chen
Ke-Ran Sun, Hui-Fang Lv, Bei-Bei Chen, Cai-Yun Nie, Jing Zhao, Xiao-Bing Chen, Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China
Author contributions: Chen XB and Lv HF were responsible for study conception and design; Sun KR, Chen BB, Nie CY and Zhao J carried out data collection and analysis; Sun KR and Chen XB drafted the article.
Supported by the National Natural Science Foundation of China, No. 81472714; and the Central Plains Thousand Talents Plan-Central Plains Leading Talent Project, No. 204200510023.
Conflict-of-interest statement: The Authors declare no conflicts of interest regarding this study.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Bing Chen, PhD, Doctor, Professor, Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, No. 127 Dong Ming Road, Zhengzhou 450008, Henan Province, China. zlyychenxb0807@zzu.edu.cn
Received: December 4, 2020
Peer-review started: December 4, 2020
First decision: February 14, 2021
Revised: February 23, 2021
Accepted: March 13, 2021
Article in press: March 13, 2021
Published online: April 15, 2021
Core Tip

Core Tip: Anthrax toxin receptor 1, also known as tumor endothelial marker 8, is a highly conserved cell surface protein overexpressed in tumor infiltrating vessels.